By Mill Chart
Last update: Jan 5, 2024
Take a closer look at PFIZER INC (NYSE:PFE), a stock of interest to dividend investors uncovered by our stock screener. NYSE:PFE excels in fundamentals and provides a decent dividend, all while maintaining a reasonable valuation. Let's break it down further.
ChartMill employs its own Dividend Rating system for all stocks. This score, on a scale of 0 to 10, is determined by evaluating different dividend factors, such as yield, historical performance, dividend growth, and sustainability. NYSE:PFE has been assigned a 7 for dividend:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NYSE:PFE has achieved a 6 out of 10:
ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NYSE:PFE was assigned a score of 8 for profitability:
Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.
Check the latest full fundamental report of PFE for a complete fundamental analysis.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
PFIZER INC
NYSE:PFE (4/26/2024, 7:09:35 PM)
After market: 25.45 +0.05 (+0.2%)25.4
+0.14 (+0.55%)
Pfizer's huge facility in Sanford produces its first FDA-approved gene therapy, which runs $3.5 million a dose.
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.
Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.
You'll get dividends and more with these great stocks.
Passive investors pay attention! Invest in the best of the best with these seven dividend stocks for steady returns.
CNBC's Jim Cramer on Friday walked investors through next week on Wall Street.
Put your money to work by investing in these three high-quality dividend stocks.
Pfizer Inc. won US approval for its first gene therapy, expanding into a promising field of medicine that has proved to be a challenging business.
The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B.
Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure.